A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Recruiting now · Phase 2
Conditions studied: Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
In brief
The purpose of this study is to investigate the tolerability of ianalumab (9 mg/kg) with investigator's choice thrombopoietin receptor agonist (IC TPO-RA) in participants diagnosed with primary immune thrombocytopenia (ITP) who have been treated with at least one but no more than four prior treatments, and with no change in IC TPO-RA dose in at least the last 14 days prior to the start of ianalumab.
Key facts
- Study ID
- NCT07421167
- Run by
- Novartis Pharmaceuticals
- People needed
- 164
- Starts
- 2026-06-29
- Expected to finish
- 2030-08-10
- Last updated by the study team
- 2026-07-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stamford Hospital — Stamford, Connecticut, United States (enrolling)
- Baptist MD Anderson Cancer Center — Jacksonville, Florida, United States (enrolling)
- DH Cancer Research Center LLC — Margate, Florida, United States (enrolling)
- Hope And Healing Care — Hinsdale, Illinois, United States (enrolling)
- Summit Medical Group — Summit, New Jersey, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.